Business Details
Innovative Non-Opioid Pain Management Solutions
SCILEX Pharmaceuticals (Nasdaq: SCLX) stands as a leader in non-opioid pain management solutions, dedicated to developing innovative pharmaceutical products that address acute and chronic pain conditions. Since our inception, we have focused on acquiring, developing, and commercializing therapies that align with rigorous social, environmental, and ethical standards. Our proprietary technologies, including advanced transdermal delivery systems and liquid formulations, optimize drug efficacy while minimizing side effects. With FDA-approved products like ZTLido for post-herpetic neuralgia, Elyxyb for migraines, and Gloperba for gout prophylaxis, we prioritize patient quality of life through precision dosing and targeted delivery.Our pipeline includes SP-102, a corticosteroid gel for sciatica with Fast Track status, and SP-104, a low-dose naltrexone for fibromyalgia. Backed by a leadership team with decades of pharmaceutical expertise, we maintain transparent operations, adhering to regulatory compliance and fostering trust through scientific integrity. Our commitment to innovation and patient-centric care positions us as a trusted partner in advancing non-opioid pain management globally.
Services
ZTLido
Elyxyb
Gloperba
SP-102
SP-104
Highlights and features
- We offer proprietary transdermal delivery systems for optimized drug efficacy.
- Our products include FDA-approved non-opioid solutions for chronic pain conditions.
- We maintain Fast Track status for pipeline candidates addressing unmet medical needs.
- Our leadership team has decades of experience in pharmaceutical development.
- We prioritize ethical, environmental, and social responsibility in product development.
Associations and certifications
- FDA
Services
ZTLido
ZTLido is a FDA-approved lidocaine topical system for post-herpetic neuralgia. Its proprietary adhesion technology ensures continuous pain relief while minimizing skin irritation. Designed for localized nerve pain, it offers a non-opioid alternative with proven efficacy.
Elyxyb
Elyxyb is a liquid celecoxib solution for acute migraine management. Its ready-to-use formulation enables precise dosing and rapid absorption. As a non-opioid option, it targets inflammation to provide fast, long-lasting relief for adults with migraines.
Gloperba
Gloperba is the first liquid colchicine formulation for preventing gout flares. Its precision dosing reduces side effects while improving patient compliance. This FDA-approved therapy offers a convenient, non-opioid solution for chronic gout management.
SP-102
SP-102 is a corticosteroid gel in Phase 3 trials for lumbosacral radicular pain. With FDA Fast Track status, it aims to replace off-label steroid injections. This non-opioid epidural treatment targets inflammation for sciatica relief.
SP-104
SP-104 is a low-dose naltrexone in development for fibromyalgia. Its delayed-release formulation modulates immune response to reduce chronic pain. This pipeline candidate addresses a significant unmet need in non-opioid pain management.
People
Henry Ji
Executive Chairman, CEO, and President
Dr. Ji has 25+ years in biotech, leading Scilex since 2019. He co-founded Sorrento Therapeutics and has driven growth through strategic acquisitions in pharmaceutical innovation.
Stephen Ma
Chief Operating Officer and CFO
Stephen Ma has 20+ years in pharmaceutical finance, joining Scilex in 2023. He previously managed finance teams at Semnur Pharmaceuticals and Anwita Biosciences, focusing on commercial and clinical operations.
Dmitri Lissin
Interim Chief Medical Officer
Dr. Lissin leads clinical development at Scilex with expertise in pain management. He has directed trials for novel analgesics and worked with the FDA to advance non-opioid therapies through regulatory pathways.
Questions
What non-opioid pain products does Scilex offer?
Scilex markets ZTLido (post-herpetic neuralgia), Elyxyb (migraines), and Gloperba (gout prophylaxis), with pipeline candidates targeting sciatica and fibromyalgia.
How do I report adverse events for Scilex medications?
Call 1-866-SCILEX3 or visit FDA's MedWatch website to report side effects or product quality issues.
Are Scilex products available outside the U.S.?
Current commercialization focuses on the U.S. market, with partnerships for potential international expansion.
What clinical trials are Scilex conducting?
Phase 3 trials for SP-102 (sciatica) and Phase 2/3 planning for SP-103 (neck pain) are ongoing.
How does Scilex ensure product quality?
We adhere to FDA regulations and maintain rigorous quality control across manufacturing, clinical development, and distribution.
